Stephen A. Hill, M.D.
Chief Executive Officer
Dr. Hill has served as our Chief Executive Officer since August of 2015. He previously served as CEO and President of Targacept, Inc., a biopharmaceutical company developing a diverse pipeline of NNR Therapeutics. In August 2015, Targacept merged with Catalyst Biosciences Inc. Prior to joining Targacept, Dr. Hill served as President of Solvay Pharmaceuticals, Inc. from 2008 to 2010. Solvay was acquired by Abbott Labs in 2010. From 1999 to 2008, Dr. Hill served as President and CEO of ArQule where he successfully implemented the company’s transition from a chemistry services platform to an integrated research and development organization. From 1997 to 1999, Dr. Hill served as Global Head of Clinical Development for Roche Products. He currently serves on the board of directors for publicly held companies Catalyst Biosciences, Cellectar Biosciences, Inc., and Lipocine, Inc. Dr. Hill earned his bachelor and medical degrees from The University of Oxford and practiced medicine in the field of orthopedic surgery prior to his career in the biopharmaceutical industry.
Mark B. Roth, Ph.D.
Mark Roth has served as our President and member of our Board of Directors since the company’s founding in 2014. Dr. Roth is a member of the Division of Basic Sciences at the Fred Hutchinson Cancer Research Center, a position he has held since 1989, and an affiliate professor in the Department of Biochemistry at the University of Washington. He is the founder of Ikaria, Inc., which was formed in 2005. Ikaria was acquired by Mallinckrodt Plc in 2015. Dr. Roth’s pioneering research has included molecular mechanisms of genetic regulation, animal physiology and medical diagnostics. Following his discovery of a class of molecules known as SR proteins, Dr. Roth developed a diagnostic assay for systemic lupus erythematosus, which received FDA approval. He is most noted for his experimental work on new clinical procedures for the temporary reduction of metabolism. In 2007, Dr. Roth was named a MacArthur fellow by the John D. and Catherine T. MacArthur Foundation. In 2007 he also received a Significant Technical Achievement Award from the Defense Advanced Research Projects Agency (DARPA) and in 2006 was an invited speaker at the White House Fellows National Meeting, Washington, D.C. Dr. Roth received a B.Sc. from the University of Oregon and a Ph.D. from the University of Colorado at Boulder.
Simon J. Tulloch, Dip Pharm Med
Chief Medical Officer
Simon Tulloch has served as our Chief Medical Officer since September 2015. He has 30 years of pharmaceutical and biotech experience in clinical development, R&D management, and business roles, both in Europe and the USA. Dr. Tulloch previously served as Chief Medical Officer of InfaCare Pharmaceutical Corporation, a specialty pharmaceutical company developing therapeutics for neonatal diseases, as well as Principal of Capital Biopharma Consulting. Prior to that, Dr. Tulloch worked for Shire Pharmaceuticals from 1996 to 2006. He served as CNS Global Business Unit Leader for Shire Pharmaceuticals from 2004 to 2006, where he was responsible for forming the CNS global business group and managing the CNS product portfolio. From 2000 to 2004, he served as Senior Vice President and Head of U.S. Research & Development at Shire and previously held positions of Vice President & Senior Director, US Medical Affairs. Prior to Shire, Dr. Tulloch was Clinical Research Director and International Product Leader, Ob Gyn at the RW Johnson Pharmaceutical Research Institute. In addition, Dr. Tulloch worked at Ortho-Cilag Ltd and Fisons Pharmaceuticals. Dr. Tulloch received a BA and MA in physiological sciences and a BM, BCh from Oxford as well as a diploma in Pharmaceutical Medicine from Royal College of Physicians of London.
Chief Financial and Business Officer
Brian Blackman has served as our Chief Financial and Business Officer since July 2016. Mr. Blackman has over 15 years of experience in the biotech industry in finance and business development and has previously served as Vice President, Finance and Administration for VLST Corporation and served as Director, Business Operations for BN ImmunoTherapeutics, Inc., a subsidiary of Bavarian Nordic, Inc. Prior to that, Mr. Blackman served as Senior Manager, Business Development for Dendreon Corporation from 2005 to 2008, joining the company in 2004 as Senior Area Finance Manager. His career in financial management has also included work at Penton Media, Inc., as senior financial analyst and Amgen, Inc., serving as financial analyst for Amgen Colorado. Mr. Blackman received a B.S. in Finance from the University of Colorado at Boulder and an M.B.A. from London Business School, UK.